Provided by Tiger Trade Technology Pte. Ltd.

Cabaletta Bio

2.57
-0.0300-1.15%
Pre-market: 2.600.0292+1.14%08:54 EST
Volume:2.01M
Turnover:5.10M
Market Cap:247.40M
PE:-1.07
High:2.61
Open:2.60
Low:2.48
Close:2.60
52wk High:3.67
52wk Low:0.9857
Shares:96.27M
Float Shares:61.64M
Volume Ratio:0.84
T/O Rate:3.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4075
EPS(LYR):-2.3627
ROE:-101.06%
ROA:-51.82%
PB:1.77
PE(LYR):-1.09

Loading ...

Analysts Offer Insights on Healthcare Companies: Cabaletta Bio (CABA) and Ocular Therapeutix (OCUL)

TIPRANKS
·
Feb 05

Cabaletta Bio to Participate in Guggenheim Emerging Outlook Biotech Summit

Reuters
·
Feb 05

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Feb 03

Cabaletta Bio, Inc. (NASDAQ:CABA) institutional owners may be pleased with recent gains after 9.7% loss over the past year

Simply Wall St.
·
Jan 22

Cabaletta Bio Insiders Go on a Buying Spree, Signaling Strong Confidence From the Top

TIPRANKS
·
Jan 22

Cabaletta Bio CEO Steven Nichtberger Reports Acquisition of Common Shares

Reuters
·
Jan 22

Cabaletta Bio Director Mark Simon Reports Acquisition of Common Shares

Reuters
·
Jan 22

Cabaletta Bio announces 2026 strategic priorities

TIPRANKS
·
Jan 12

Cabaletta Bio Outlines 2026 Strategy Focused on Enrolling Pivotal Myositis Trial, Advancing Outpatient and No Preconditioning Rese-cel Therapies, and Scaling Automated Manufacturing for Autoimmune Disease Pipeline

Reuters
·
Jan 12

Press Release: Cabaletta Bio Announces 2026 Strategic Priorities

Dow Jones
·
Jan 12

FDA Clears IND Amendment for Cabaletta Bio’s Rese-cel Clinical Manufacturing

Reuters
·
Jan 12

Ind Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms

THOMSON REUTERS
·
Jan 12

Cabaletta Bio Unveils Plans for CD19 Cell Therapies Targeting Autoimmune Diseases

Reuters
·
Dec 07, 2025

Guggenheim Sticks to Its Buy Rating for Cabaletta Bio (CABA)

TIPRANKS
·
Nov 14, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 12, 2025

Cabaletta Bio (CABA) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Nov 11, 2025

Cabaletta Bio Advances in Autoimmune Therapy Development

TIPRANKS
·
Nov 11, 2025

Cabaletta Bio: Promising Clinical Progress and Strategic Advancements Drive Buy Rating

TIPRANKS
·
Nov 11, 2025

Cabaletta Bio reports smaller-than-expected Q3 loss

Reuters
·
Nov 10, 2025

Cabaletta Bio reports Q3 EPS (44c), consensus (46c)

TIPRANKS
·
Nov 10, 2025